Global Primary Membranous Nephropathy (PMN) Market Outlook

Thelansis’s “Global Primary Membranous Nephropathy (PMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Membranous Nephropathy treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Primary Membranous Nephropathy (PMN) Overview

Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults, characterised by immune complex deposition along the glomerular basement membrane subepithelial surface, driven predominantly by autoantibodies — most critically anti-PLA2R antibodies, present in approximately 70-80% of cases — targeting podocyte antigens, activating complement, and disrupting the glomerular filtration barrier. Anti-THSD7A antibodies account for a further subset, with additional novel antigenic targets increasingly recognised. Patients present with insidious-onset nephrotic syndrome — heavy proteinuria, hypoalbuminaemia, peripheral oedema, and hyperlipidaemia — with significant risks of thromboembolic complications, particularly renal vein thrombosis, and progressive chronic kidney disease. Diagnosis integrates renal biopsy demonstrating characteristic subepithelial deposits on electron microscopy, with anti-PLA2R antibody titres serving as both diagnostic and disease activity monitoring biomarkers. Spontaneous remission occurs in approximately one-third of patients, justifying an initial conservative approach with optimised renin-angiotensin-aldosterone system blockade, lipid management, and anticoagulation where indicated. Immunosuppressive therapy — historically cyclophosphamide-based Ponticelli regimen or calcineurin inhibitors — is reserved for persistent or high-risk proteinuria. Rituximab, targeting CD20-positive B-cells to suppress autoantibody production, has emerged as the preferred first-line immunosuppressive strategy given favourable efficacy and tolerability. Prognosis is variable; regular proteinuria and anti-PLA2R titre monitoring, nephrology surveillance, and patient-centred cardiovascular and renal risk optimisation underpin long-term management.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)